Drug intelligence / Profile preview

AZD0233

Development stage: Phase 1
Lead developer: AstraZeneca
Modality: Small Molecules
Administration: Oral

Overview

AZD0233 is an investigational small molecule drug developed by AstraZeneca for the treatment of dilated cardiomyopathy. It is administered orally and acts by targeting the chemokine receptor CX3CR1. As of March 2025, AZD0233 is in Phase I clinical trials to assess its safety, tolerability, and pharmacokinetics in healthy adult participants. The primary therapeutic area under investigation is cardiovascular disease, specifically dilated cardiomyopathy.

Targets

CX3CR1 (C-X3-C motif chemokine receptor 1)

Beyond the preview

Go deeper on AZD0233.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AZD0233.

Explore the full profile